Cohance Life Gets US FDA Inspection Report With Voluntary Action Indicated Tag

Cohance Lifesciences Ltd (formerly Suven Pharmaceuticals) said it received an Establishment Inspection Report (EIR) from the US FDA for its Unit-IV facility in Nacharam, Hyderabad. The inspection took place from March 3 to March 7.

The FDA’s voluntary action indicated (VAI) tag means the regulator found some objectionable conditions during the inspection but is not recommending any immediate regulatory action. The company has time to voluntarily address these issues.

Cohance Lifesciences reaffirmed its commitment to maintaining high quality and regulatory standards.

The company was renamed following its acquisition by private equity firm Advent International, which merged it with Cohance effective May 1.